Phathom Pharmaceuticals, Inc. (PHAT)

12.17 -0.50 (-3.95%) USD  |  NASDAQ  |  May 07, 10:58
More

Phathom Pharmaceuticals SG&A Expense (TTM) : 239.25M for March 31, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for PHAT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Replimune Group, Inc. 103.07M
ANI Pharmaceuticals, Inc. 317.74M
MannKind Corp. 229.86M
Ocugen, Inc. 21.13M
Ligand Pharmaceuticals, Inc. 92.45M